Shattuck Labs Inc (STTK) - News Archive

Shattuck Labs: Pioneering Advancements in Targeting Immune Responses and Cancer PathwaysIn the ever-evolving landscape of biotechnology, Shattuck Labs, Inc. (NASDAQ: STTK) stands as a beacon of innovation, committed to...

Innovative Therapies in the Spotlight: Shattuck Labs Pioneering DR3 Antagonist and New Insights into SL-172154 The biotechnology sector is on a relentless quest to develop innovative drug therapies for complex and life-...

Shattuck Labs Announces Promising Interim Data from Phase 1B Clinical Trial of SL-172154 in Combination with Azacitidine for the Treatment of HR-MDS and TP53 Mutant AML Shattuck Labs, a biopharmaceutical company focused...

In the ever-evolving landscape of oncology, the quest for novel therapies that demonstrate both efficacy and safety remains a paramount concern. Recently, Shattuck Labs has made significant strides in this realm, as evi...

CSIMarket.com presents a summary of the promising results from Shattuck Labs Phase 1B dose expansion clinical trial involving SL-172154 and Azacitidine (AZA) in frontline higher-risk Myelodysplastic Syndromes (HR-MDS) a...

In an unprecedented oral presentation at the highly esteemed American Association for Cancer Research (AACR) Annual Meeting 2024, Shattuck Labs, a biomedical research powerhouse, has unveiled groundbreaking preclinical...

In a groundbreaking move, Shattuck Labs, Inc. (Shattuck) has joined forces with Ono Pharmaceutical Co., Ltd. (Ono) to explore the potential of bifunctional fusion proteins as a novel therapeutic approach for patients su...

Shattuck Labs Poised for Success: Key Milestones and Soaring Stock PricesShattuck Labs, a leading biotechnology company specializing in the development of bi-functional fusion proteins, recently released a corporate upd...

Shattuck Labs, Inc. has recently transfixed the medical community after revealing striking initial topline indications from its ongoing Phase 1 A/B Dose Expansion Clinical Trial. The trial, centered on its product SL-17...